Global Laboratory-developed Testing Market Strategic Research Report

Scope of the Report

The global Laboratory-developed Testing market size is predicted to grow from US$ 4,032 million in 2025 to US$ 5,189 million in 2032; it is expected to grow at a CAGR of 3.7% from 2026 to 2032.

Twenty-five years ago, the Food and Drug Administration (FDA) asserted in a draft document that "home brew" tests-now commonly referred to as laboratory-developed tests (LDTs)-are subject to the same regulatory oversight as other in vitro diagnostics (IVDs)4. In 2010, the FDA began work on developing a proposed framework for future LDT oversight. Released in 2014, the draft guidance sparked an intense debate over potential LDT regulation. While the proposed guidance has not been implemented, many questions regarding LDT oversight remain unresolved.

A laboratory developed test (LDT) is a type of in vitro diagnostic test that is designed, manufactured and used within a single laboratory.

LDTs can be used to measure or detect a wide variety of analytes (substances such as proteins, chemical compounds like glucose or cholesterol, or DNA), in a sample taken from a human body. Some LDTs are relatively simple tests that measure single analytes, such as a test that measures the level of sodium. Other LDTs are complex and may measure or detect one or more analytes. For example, some tests can detect many DNA variations from a single blood sample, which can be used to help diagnose a genetic disease. Various levels of chemicals can be measured to help diagnose a patient’s state of health, such as levels of cholesterol or sodium.

While the uses of an LDT are often the same as the uses of FDA-cleared or approved in vitro diagnostic tests, some labs may choose to offer their own test. For example, a hospital lab may run its own vitamin D assay, even though there is an FDA-cleared test for vitamin D currently on the market.

The leading players in laboratory-developed testing include Quest Diagnostics, Roche, Illumina, Qiagen, and Eurofins, with the top three accounting for approximately 15% of the market.

North America is the largest market with more than 65% of the market, followed by Europe with about 15%.

This report presents a comprehensive overview of the global Laboratory-developed Testing market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Commercial Service
• R&D

Segment by players, this report covers

• Adaptive Biotechnologies Corporation
• Quest Diagnostics
• Roche
• Illumina
• Qiagen
• Eurofins
• Guardant Health
• Biotheranostics
• Adaptive Biotechnologies
• Rosetta Genomics
• Biodesix
• Helix

Segment by Application

• Genetic Testing
• Oncology
• Infectious Disease
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Laboratory-developed Testing market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Genetic Testing, Oncology, Infectious Disease evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact